Hot Results
- Quick Search
- Large-scale studies
- Genome-wide Association Studies of ADHD
- Genome-wide Linkage Studies of ADHD
- Genome-wide CNV Analyses of ADHD
- Meta-analysis Studies of ADHD
- Data Summary
KEGG Pathway Report
Basic Info
| ID | hsa04664 |
|---|---|
| Name | Fc epsilon RI signaling pathway |
| Description | Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation pathways are regulated both positively and negatively by the interactions of numerous signaling molecules. Mast cells that are thus activated release preformed granules which contain biogenic amines (especially histamines) and proteoglycans (especially heparin). The activation of phospholipase A2 causes the release of membrane lipids followed by development of lipid mediators such as leukotrienes (LTC4, LTD4 and LTE4) and prostaglandins (especially PDG2). There is also secretion of cytokines, the most important of which are TNF-alpha, IL-4 and IL-5. These mediators and cytokines contribute to inflammatory responses. |
| No. of Genes in ADHDgene | 20 |
| Source | Pathway by Database Search |
Pathway related genes in ADHDgene (count: 20)
Literature-origin genes (count: 1)
| Approved Symbol | Approved Name | Location | No. of Studies (significant/non-significant/trend)  |
|---|---|---|---|
| MAP2K3 | mitogen-activated protein kinase kinase 3 | 17q11.2 | 1(0/1/0) |
Genes from other sources (count: 19)
| Approved Symbol | Approved Name | Location | Source |
|---|---|---|---|
| PRKCB | protein kinase C, beta | 16p12 | Mapped by significant region |
| MAPK9 | mitogen-activated protein kinase 9 | 5q35 | Mapped by CNV |
| PLA2G2A | phospholipase A2, group IIA (platelets, synovial fluid) | 1p35 | Mapped by PBA pathway |
| PLA2G1B | phospholipase A2, group IB (pancreas) | 12q23-qter | Mapped by PBA pathway |
| PLA2G2E | phospholipase A2, group IIE | 1p36.13 | Mapped by PBA pathway |
| PLA2G2D | phospholipase A2, group IID | 1p36.12 | Mapped by PBA pathway |
| MAPK3 | mitogen-activated protein kinase 3 | 16p11.2 | Mapped by CNV |
| PLA2G4B | phospholipase A2, group IVB (cytosolic) | 15q11.2-q21.3 | Mapped by PBA pathway |
| PLA2G3 | phospholipase A2, group III | 22q12.2 | Mapped by PBA pathway |
| PLA2G5 | phospholipase A2, group V | 1p36-p34 | Mapped by PBA pathway |
| PLA2G10 | phospholipase A2, group X | 16p13.1-p12 | Mapped by PBA pathway; Mapped by significant region |
| PLA2G6 | phospholipase A2, group VI (cytosolic, calcium-independent) | 22q13.1 | Mapped by PBA pathway |
| MS4A2 | membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta polypeptide) | 11q12-q13 | Mapped by PBA pathway; Mapped by significant region |
| MAPK1 | mitogen-activated protein kinase 1 | 22q11.2 | Mapped by LD-proxy |
| PIK3R1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 5q13.1 | Mapped by significant region |
| GAB2 | GRB2-associated binding protein 2 | 11q13.4-q13.5 | Mapped by significant region |
| PIK3CG | phosphoinositide-3-kinase, catalytic, gamma polypeptide | 7q22 | Mapped by CNV |
| SYK | spleen tyrosine kinase | 9q22 | Mapped by significant region |
| PLCG2 | phospholipase C, gamma 2 (phosphatidylinositol-specific) | 16q24.1 | Mapped by significant region |